[Experience in the prolonged use of midantan (amantadine hydrochloride) in parkinsonism].
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D004576:Electromyography; D004837:Epinephrine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009129:Muscle Tonus; D009638:Norepinephrine / Q000097:blood; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy*; D010301:Parkinson Disease, Postencephalitic / Q000097:blood / Q000188:drug therapy
D000547:Amantadine; D009638:Norepinephrine; D004837:Epinephrine
Opyt dlitel'nogo primeneniia midantana (amantadina-gidrokhlorida) pri parkinsonizme.